Calmare Therapeutics Appoints Christine Chansky, M.D., J.D., F.C.L.M., Chief Regulatory Officer

FAIRFIELD, Conn.--(BUSINESS WIRE)--Calmare Therapeutics Incorporated, (OTCQB:CTTC) (CTI), the Calmare® chronic pain and wound care company, has appointed Dr. Christine Chansky, M.D., J.D., F.C.L.M., chief regulatory officer (CRO) of Calmare Therapeutics.

Suggested Articles

With stints at Genzyme, Bayer and, most recently, TranScrip Partners, Gilbert Wagener, M.D., Ph.D., is now signing up to U.K. biotech Rexgenero.

After kick-starting its first-in-human test back in March, Bolt Therapeutics has nabbed a meaty $93.5 million round to help fund its clinical work.

Antivirals from Roche, Bristol Myers Squibb, Viiv and Gilead, or modified versions of them, could prove effective against COVID-19, researchers said.